Welcome to our dedicated page for AMERISOURCEBERGEN news (Ticker: abc), a resource for investors and traders seeking the latest updates and insights on AMERISOURCEBERGEN stock.
Cencora, Inc. (NYSE: COR) is a global pharmaceutical solutions leader driving innovation across healthcare supply chains. This page provides investors and industry professionals with essential updates on Cencora's strategic initiatives, financial developments, and operational milestones.
Access real-time press releases and analysis covering Cencora's pharmaceutical services, including distribution network expansions, biopharma partnerships, and regulatory advancements. Track key developments such as acquisitions in specialty healthcare, global commercialization efforts, and social responsibility programs through the Cencora Impact Foundation.
Stay informed about critical updates including earnings reports, supply chain innovations, and strategic investments like the OneOncology and PharmaLex acquisitions. Our curated news collection ensures you never miss developments impacting Cencora's position as a Fortune 500 healthcare leader operating in 50+ countries.
Bookmark this page for streamlined access to verified updates about Cencora's pharmaceutical distribution services, venture capital activities through Cencora Ventures, and initiatives advancing global healthcare access. Check regularly for authoritative insights into this NYSE-listed industry pioneer.
AmerisourceBergen has launched a new Cell and Gene Therapy (CGT) Integration Hub, designed to enhance connectivity throughout the treatment journey for patients and providers. This platform-agnostic system integrates with biopharma and provider platforms, facilitating real-time data exchange and improving care coordination.
The CGT Integration Hub expedites benefits investigations, offers real-time visibility into therapy statuses, and proactively alerts case managers regarding treatment changes. It aims to streamline the path-to-care process, helping healthcare professionals manage the urgency and complexity of cell and gene therapies.
Moreover, AmerisourceBergen continues to support CGT developers through logistics, regulatory consulting, and market access services, reinforcing its commitment to advancing innovation in the pharmaceutical supply chain.
AmerisourceBergen (NYSE: ABC) has announced a partnership with TPG to acquire OneOncology, a prominent oncology network valued at $2.1 billion. Under this agreement, TPG will gain a majority interest in OneOncology, while AmerisourceBergen will hold a minority interest, investing approximately $685 million in cash for about 35% ownership. The acquisition aims to enhance AmerisourceBergen's relationships with community oncology practices and expand its specialty solutions. The deal is expected to close by September 2023, subject to regulatory approvals. Importantly, it may contribute to AmerisourceBergen's adjusted diluted EPS within the first year after the closing.
AmerisourceBergen Corporation (NYSE: ABC) is set to announce its Second Quarter Fiscal 2023 results on May 2, 2023, before market opening. The company will host a conference call at 8:30 a.m. ET on the same day, featuring CEO Steven H. Collis and CFO James F. Cleary. Participants can access the call via telephone or through a live webcast available on the investor.amerisourcebergen.com website. A replay will also be available post-call, ensuring stakeholders can stay informed about the company's performance.
X-energy Reactor Company, LLC has appointed Christopher Ginther and Kathleen Hyle to its Board of Directors, effective immediately. Ginther, from Ontario Power Generation, has invested $40 million in X-energy since 2021, while Hyle brings extensive governance experience from AmerisourceBergen and Bunge Limited. This leadership change coincides with X-energy's transition to a public company through a merger with Ares Acquisition Corporation (AAC), anticipated to close in Q2 2023. The Board aims to leverage their expertise to navigate growth in the advanced nuclear energy sector and achieve net-zero goals by 2040.
AmerisourceBergen Corporation (NYSE: ABC) reported revenues of $62.8 billion for the first quarter of fiscal year 2023, marking a 5.4% increase compared to the same period last year. The GAAP diluted EPS reached $2.33, up from $2.13 year-over-year. The adjusted diluted EPS rose by 5.0% to $2.71, compared to $2.58 in the prior year. Additionally, the company has raised its adjusted diluted EPS guidance for fiscal 2023 to a range of $11.50 to $11.75.
AmerisourceBergen (NYSE: ABC) has announced its intent to change its name to Cencora, aiming to better reflect its global reach and purpose-driven approach to healthcare. The rebranding is part of the company's growth strategy, intended to unify its identity and enhance its impact across the pharmaceutical supply chain. The name change is expected to take place in the second half of 2023. Cencora symbolizes a commitment to innovation and patient access, fostering a more inclusive experience for employees and strengthening the employer brand. The company continues to focus on pharmaceutical distribution and support for biopharma services.
AmerisourceBergen (NYSE:ABC) has entered into a partnership with Civica, Inc. to serve as its exclusive distribution partner. This collaboration aims to enhance the supply chain for Civica's products, ensuring critical generic medications are delivered efficiently and reliably to healthcare providers across the U.S. The phased rollout of this partnership is set to occur throughout the first half of 2023. AmerisourceBergen, with over 100 years in pharmaceutical supply chain operations and a network of more than 50 U.S. facilities, intends to leverage its resources to support Civica’s mission of improving access to essential medications.
AmerisourceBergen Corporation (NYSE: ABC) will release its First Quarter Fiscal 2023 results on February 1, 2023, before the market opens. A conference call to discuss these results is scheduled for 8:30 a.m. ET the same day, featuring Steven H. Collis, CEO, and James F. Cleary, CFO. The call can be accessed via telephone or webcast on the company’s investor site. AmerisourceBergen, ranked #10 on the Fortune 500, generates over $200 billion in annual revenue, focusing on pharmaceuticals and healthcare solutions.
AmerisourceBergen Corporation (NYSE: ABC) has successfully completed its acquisition of PharmaLex Holding GmbH, enhancing its growth strategy. This acquisition strengthens AmerisourceBergen's leadership in specialty services and expands its global pharmaceutical manufacturer capabilities. The addition of PharmaLex's regulatory affairs, development consulting, pharmacovigilance, and compliance services positions AmerisourceBergen as a leading partner for biopharmaceutical companies throughout the drug development and commercialization process.
